NCT02326168View on ClinicalTrials.gov

PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Bladder Cancer
Interventions
DRUG

Bacillus Calmette-Guerin (BCG)

Intravesical instillation for non-muscle invasive bladder cancer

Trial Locations (1)

78229

The University of Texas Health Science Center, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02326168 - PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer | Biotech Hunter | Biotech Hunter